| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
|
Veeraraghavan, J.
|
|
|
30 |
6 |
p. 927-933
|
artikel
|
| 2 |
Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors
|
Marcucci, G.
|
|
|
30 |
6 |
p. 908-920
|
artikel
|
| 3 |
Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma
|
King, A.D.
|
|
|
30 |
6 |
p. 977-982
|
artikel
|
| 4 |
Corrections to “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer”
|
Wu, Y.
|
|
|
30 |
6 |
p. 1019
|
artikel
|
| 5 |
Corrections to “Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial”
|
Shi, W.
|
|
|
30 |
6 |
p. 1018
|
artikel
|
| 6 |
Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
|
Baselga, J.
|
|
|
30 |
6 |
p. 1017
|
artikel
|
| 7 |
Corrections to “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors”
|
Soria, J.-C.
|
|
|
30 |
6 |
p. 1020
|
artikel
|
| 8 |
Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab”
|
Lenihan, D.
|
|
|
30 |
6 |
p. 1021
|
artikel
|
| 9 |
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
|
Guarneri, V.
|
|
|
30 |
6 |
p. 921-926
|
artikel
|
| 10 |
Divining responder populations from survival data
|
Rahman, R.
|
|
|
30 |
6 |
p. 1005-1013
|
artikel
|
| 11 |
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial
|
Hrebien, S.
|
|
|
30 |
6 |
p. 945-952
|
artikel
|
| 12 |
Editorial board
|
|
|
|
30 |
6 |
p. ii-iii
|
artikel
|
| 13 |
ER+/HER2+ breast cancer: are we really de-escalating?
|
de Azambuja, E.
|
|
|
30 |
6 |
p. 875-877
|
artikel
|
| 14 |
Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma
|
Xu, L.X.
|
|
|
30 |
6 |
p. 990-997
|
artikel
|
| 15 |
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
|
Peters, S.
|
|
|
30 |
6 |
p. 884-896
|
artikel
|
| 16 |
Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens
|
Hannigan, B.
|
|
|
30 |
6 |
p. 963-969
|
artikel
|
| 17 |
NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis
|
Yin, C.
|
|
|
30 |
6 |
p. 953-962
|
artikel
|
| 18 |
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
|
Trebeschi, S.
|
|
|
30 |
6 |
p. 998-1004
|
artikel
|
| 19 |
Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?
|
Deutsch, E.
|
|
|
30 |
6 |
p. 879-881
|
artikel
|
| 20 |
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|
Fradet, Y.
|
|
|
30 |
6 |
p. 970-976
|
artikel
|
| 21 |
Revisiting surveillance schemes for cancer survivors
|
Holme, Ø.
|
|
|
30 |
6 |
p. 881-883
|
artikel
|
| 22 |
Table of Contents
|
|
|
|
30 |
6 |
p. ii-iii
|
artikel
|
| 23 |
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
|
Messaoudene, M.
|
|
|
30 |
6 |
p. 934-944
|
artikel
|
| 24 |
T-cell bispecific antibodies to bypass MHC class I loss in breast cancer
|
Marra, A.
|
|
|
30 |
6 |
p. 877-879
|
artikel
|
| 25 |
The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case–control and Mendelian randomization study in the European prospective investigation into cancer and nutrition
|
Smith Byrne, K.
|
|
|
30 |
6 |
p. 983-989
|
artikel
|
| 26 |
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
|
Ay, C.
|
|
|
30 |
6 |
p. 897-907
|
artikel
|
| 27 |
Vemurafenib and cobimetinib combination therapy for BRAF V600E-mutated melanoma favors posterior reversible encephalopathy syndrome
|
Engel, S.
|
|
|
30 |
6 |
p. 1014-1016
|
artikel
|
Tijdschrift beschrijving